Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF
暂无分享,去创建一个
O. Fedorov | S. Müller | G. Nunez-Alonso | C. Tallant | P. Savitsky | Catherine Rogers | Octovia P. Monteiro | James Bennett | Julia Meier | Vicky Gamble | Bernard Haendler | Paul E. Brennan | Stefan Knapp
[1] Zhen-ning Wang,et al. TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance , 2015, Virchows Archiv.
[2] Lewis R. Vidler,et al. Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B , 2015, Journal of medicinal chemistry.
[3] Hua Yu,et al. Knockdown of Tripartite Motif Containing 24 by Lentivirus Suppresses Cell Growth and Induces Apoptosis in Human Colorectal Cancer Cells , 2014, Oncology research.
[4] S. Carr,et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer , 2014, Science.
[5] David J. Fallon,et al. 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. , 2014, ACS medicinal chemistry letters.
[6] Parantu K. Shah,et al. TRIM24 links glucose metabolism with transformation of human mammary epithelial cells , 2014, Oncogene.
[7] A. Gingras,et al. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching , 2014, Epigenetics & Chromatin.
[8] S. Knapp,et al. Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.
[9] Stefan Knapp,et al. A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced-Fit Pocket Stabilized by a Cation–π Interaction** , 2014, Angewandte Chemie.
[10] S. Knapp,et al. Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.
[11] John L Markley,et al. Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. , 2014, Journal of molecular biology.
[12] L. Wodicka,et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology , 2014, Nature chemical biology.
[13] S. Olesen,et al. Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors , 2014, ACS chemical biology.
[14] Jin-xiang Cheng,et al. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway , 2014, Oncogene.
[15] Yu Huang,et al. Overexpression of TRIM24 Is Associated with the Onset and Progress of Human Hepatocellular Carcinoma , 2014, PloS one.
[16] S. Knapp,et al. [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains , 2013, Journal of medicinal chemistry.
[17] S. Knapp,et al. Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening , 2013, Journal of medicinal chemistry.
[18] S. Knapp,et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.
[19] L. Mao,et al. TRIM24 Overexpression Is Common in Locally Advanced Head and Neck Squamous Cell Carcinoma and Correlates with Aggressive Malignant Phenotypes , 2013, PloS one.
[20] Reid C Thompson,et al. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.
[21] Stefan Knapp,et al. The bromodomain interaction module , 2012, FEBS letters.
[22] Nathan Brown,et al. Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.
[23] Ying Xu,et al. Overexpression of TRIM24 Correlates with Tumor Progression in Non-Small Cell Lung Cancer , 2012, PloS one.
[24] A. Gingras,et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.
[25] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[26] Stefan Knapp,et al. Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.
[27] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[28] C. Rice,et al. Suppression of inflammation by a synthetic histone mimic , 2010, Nature.
[29] D. Patel,et al. TRIM24 links a noncanonical histone signature to breast cancer , 2010, Nature.
[30] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[31] J. Qin,et al. Trim24 targets endogenous p53 for degradation , 2009, Proceedings of the National Academy of Sciences.
[32] Jessica Zucman-Rossi,et al. Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha , 2007, Nature Genetics.
[33] F. Jeanmougin,et al. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. , 1996, The EMBO journal.
[34] Stefan Knapp,et al. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.